IRIS
FERRARINI, MANLIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.513
Totale 11.513
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.513
Totale 11.513
Salva come PNG Salva come JPEG
Città #
Genova 8.373
Genoa 1.230
Rapallo 1.141
Vado Ligure 752
Bordighera 17
Totale 11.513
Salva come PNG Salva come JPEG
Nome #
More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia. 168
B CELL CHRONIC LYMPHOCYTIC LEUKEMIA: Lessons Learned from Studies of the B Cell Antigen Receptor. 166
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. 162
Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. 161
B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. 148
Chronic lymphocytic leukemia: a proliferation of B cells at two distinct stages of differentiation 146
Igs expressed by chronic lymphocytic leukemia B cells show limited binding-site structure variability. 145
APOPTOSIS OR PLASMA CELL DIFFERENTIATION OF CD38-POSITIVE B-CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDUCED BY CROSS-LINKING OF SURFACE IGM OR IGD 140
Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: implications for lymphomagenesis in acquired immunodeficiency syndrome. 137
Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. 135
Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. 134
The CD38 ectoenzyme family: advances in basic science and clinical practice 131
BAFF serum level predicts time to first treatment in early chronic lymphocytic leukemia. 131
Accumulation of clonally-related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients 130
B lymphocytes in humans express ZAP-70 when activated in vivo. 127
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. 125
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) 125
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. 122
B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP-70 determination on bone marrow biopsies 121
The human marginal zone B cell 121
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. 121
Analysis of the stepwise genetic changes that occurred in an AIDS-related Burkitt\'s lymphoma. 120
CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. 120
CD38 and chronic lymphocytic leukemia: a decade later. 119
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence 119
CD 10 is a marker for cycling cells with propensity to apoptosis in childhood ALL 118
A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients. 118
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells 118
Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. 115
Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. 115
Chronic lymphocytic leukaemia 115
Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. 115
SUBEPITHELIAL B CELLS IN THE HUMAN PALATINE TONSIL. II. FUNCTIONAL CHARACTERIZATION 115
Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification. 114
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. 113
Patients Treated with Rituximab-Containing Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to Influenza Vaccine Associated with a Persistent Depletion of B Memory Cells 112
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. 112
PNAEμ can significantly reduce Burkitt’s Lymphoma tumor burden in a SCID mice model: cells dissemination similar to the human disease 111
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia 110
A phase II trial with Cisplatin-Paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. 110
Immunoglobulin Gene Mutation Patterns and Heterogeneity of Marginal Zone Lymphoma 109
Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukaemia. 109
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. 109
Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma. 108
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia 108
Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. 107
Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. 107
Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B-cells 107
Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. 107
Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas 106
An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0. 106
Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. 106
Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T cell cross-priming, depending on their capacity to activate dendritic cells. 105
Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. 105
Apoptosis of Burkitt\'s lymphoma cells induced by specific interaction of surface IgM with a self-antigen. Implications for lymphomagenesis in AIDS. 105
Chromosome aberrations evaluated by comparative genomic hybridization in B cell chronic lymphocytic leukemia: correlation with CD38 expression 101
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 101
Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. 100
Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia. 100
Clinical and laboratory parameters that define clinically relevant B-CLL subgroups. 100
Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients. 100
The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein. 99
Late Epstein-Barr virus infection of a hepatosplenic gamma delta T-cell lymphoma arising in a kidney transplant recipient. 99
Recent views on B cell chronic lymphocytic leukemia pathophysiology 98
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. 98
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study. 97
Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma 97
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates pro-apoptotic signals in chronic lymphocytic leukemia B cells 96
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy 96
Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc 95
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. 95
Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements 94
IMMUNOGLOBULIN V GENE MUTAITON STATUS AND CD38 EXPRESSION AS NOVEL PROGNOSTIC INDICATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA 94
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways 94
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia 94
Identification of three subgroups of B-CELL chronic lymphocytic leukemia based upon mutations of BCL-6 and Ig V genes 93
Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era 93
Immunoglobulin V genes and CD38 expression analysis in B cell chronic lymphocytic leukemia. Blood. Letter 91
Serum-associated inhibition of neutrophil Fc receptors in cancer patients. 90
Impaired Humoral Response to Influenza Vaccine and Prolonged B Memory Cell Depletion as a Consequence of Rituximab-based Immunochemotherapy in non-Hodgkin Lymphoma Patients 89
Frequent mutation of the 5’ noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas 88
CASE 1. Complete remission to corticosteroids in an octreotide-refractory thymoma 88
Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. 88
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in earlychronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL)experience. 87
CD38 EXPRESSION DISTINGUISHES TWO GROUPS OF B CELL-CHRONIC LYMPHOCYTIC LEUKEMIAS WITH DIFFERENT RESPONSE TO ANTI IgM ANTIBODIES AND PROPENSITY TO APOPTOSIS 86
TRANSFECTION OF THE C-MYC ONCOGENE INTO NORMAL EBV-HARBORING B CELLS RESULTS IN NEW PHENOTYPIC AND FUNCTIONAL FEATURES RESEMBLING THOSE OF BURKITT LYMPHOMA CELLS AND NORMAL CENTROBLASTS 85
Chronic lymphocytic leukemia 84
Lack of mutagenicity and clastogenicity of PNAEmu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma 84
Heterogeneous expression and function ofIL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. 84
Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. 83
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases 82
Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. Haematologica 81
CD5(+) B cells with the features of subepithelial B cells found in human tonsils 80
null 78
Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia 77
Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach 76
In vitro stimulation of human tonsillar subepithelial B cell: requirement for interaction with activated T cells 71
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients 71
The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar. 70
Examples of in vivo isotype switching in IgM+ chronic lymphocytic leukemia B cells 69
Totale 10.705
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.802
article - articoli 32.245
book - libri 0
conference - conferenze 288
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 269
Totale 65.604
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.395 0 0 0 0 0 0 0 165 255 486 359 130
2020/2021725 49 67 67 52 48 58 47 74 71 89 47 56
2021/20221.239 46 75 91 141 42 69 80 305 53 132 34 171
2022/20231.375 140 91 11 173 228 271 6 124 249 6 65 11
2023/2024663 24 97 13 62 72 135 36 38 28 19 49 90
2024/20251.138 51 157 51 129 227 201 167 155 0 0 0 0
Totale 11.613